A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations

Proteomics

Volumn 15, Issue 2-3, 2015, Pages 318-326

  Blair, Brian G ^a   Wu, Xinyan ^b   Zahari, Muhammad Saddiq ^b   Mohseni, Morassa ^a   Cidado, Justin ^a,d   Wong, Hong Yuen ^a   Beaver, Julia A ^a   Cochran, Rory L ^a   Zabransky, Daniel J ^a   Croessmann, Sarah ^a   Chu, David ^a   Toro, Patricia Valda ^a   Cravero, Karen ^a   Pandey, Akhilesh ^b   Park, Ben Ho ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Johns Hopkins University   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Biomedicine; HER3; MAP kinase; PI3 kinase; PIK3CA

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GLUTAMIC ACID; GROWTH FACTOR; HISTIDINE; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; TYROSINE; UNCLASSIFIED DRUG; ERBB3 PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ARTICLE; BREAST EPITHELIUM CELL; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MEDIATOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEOMICS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATIC CELL; SOMATIC MUTATION; BREAST TUMOR; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEOMICS; RECEPTOR, ERBB-3; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84921418516     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400342     Document Type: Article

References (24)

1. Bachman, K. E., Argani, P., Samuels, Y., Silliman, N. et al., The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3, 772-775.
2. Cancer Genome Atlas, N., Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61-70.
3. Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W. et al., The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274.
4. Yi, K. H., Axtmayer, J., Gustin, J. P., Rajpurohit, A., Lauring, J., Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Oncotarget 2013, 4, 29-34.
5. Zhao, L., Vogt, P. K., Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA 2008, 105, 2652-2657.
6. Yasuda, H., Park, E., Yun, C. H., Sng, N. J. et al., Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 2013, 5, 216ra177.
7. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N. et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304, 554.
8. Soule, H. D., Maloney, T. M., Wolman, S. R., Peterson, W. D., Jr. et al., Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990, 50, 6075-6086.
9. Gustin, J. P., Karakas, B., Weiss, M. B., Abukhdeir, A. M. et al., Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc. Natl. Acad. Sci. USA 2009, 106, 2835-2840.
10. Zhong, J., Kim, M. S., Chaerkady, R., Wu, X. et al., TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol. Cell. Proteomics 2012, 11, M112.017764.
11. Kim, M. S., Zhong, Y., Yachida, S., Rajeshkumar, N. V. et al., Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Mol. Cell. Proteomics 2014, 13, 2803-2811.
12. Abukhdeir, A. M., Vitolo, M. I., Argani, P., De Marzo, A. M. et al., Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc. Natl. Acad. Sci. USA 2008, 105, 288-293.
13. Konishi, H., Karakas, B., Abukhdeir, A. M., Lauring, J. et al., Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res. 2007, 67, 8460-8467.
14. Lauring, J., Abukhdeir, A. M., Konishi, H., Garay, J. P. et al., The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008, 111, 856-864.
15. Karakas, B., Weeraratna, A. T., Abukhdeir, A. M., Konishi, H. et al., p21 Gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biol. Ther. 2007, 6, 1025-1030.
16. Wang, G. M., Wong, H. Y., Konishi, H., Blair, B. G. et al., Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013, 73, 3248-3261.
17. Huang da, W., Sherman, B. T., Lempicki, R. A., Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37, 1-13.
18. Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S. et al., H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 2010, 29, 5193-5203.
19. Chakrabarty, A., Sanchez, V., Kuba, M. G., Rinehart, C., Arteaga, C. L., Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. USA 2012, 109, 2718-2723.
20. Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G. et al., Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. USA 2013, 110, 14372-14377.
21. Hao, Y., Wang, C., Cao, B., Hirsch, B. M. et al., Gain of interaction with IRS1 by p110alpha-helical domain mutants is crucial for their oncogenic functions. Cancer Cell. 2013, 23, 583-593.
22. Huang, C. H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y. et al., The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 2007, 318, 1744-1748.
23. Guarneri, V., Generali, D. G., Frassoldati, A., Artioli, F. et al., Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J. Clin. Oncol. 2014, 32, 1050-1057.
24. Zabransky, D. J., Park, B. H., Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. J. Clin. Oncol. 2014, 32, 1084-1086.